NoNO 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
nerinetide (NA 1) / NoNO
FRONTIER, NCT02315443: Field Randomization of Nerinetide (NA-1) Therapy in Early Responders

Completed
3
532
Canada
Nerinetide (NA-1), Placebo
NoNO Inc., Brain Canada, Djavad Mowafaghian Centre for Brain Health, Canadian Stroke Network, University of Calgary, University of Toronto, University of British Columbia, Genome British Columbia
Acute Cerebral Ischemia
03/23
03/23
ESCAPE-NEXT, NCT04462536 / 2020-002360-30: Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis

Completed
3
850
Europe, Canada, US, RoW
Placebo, Nerinetide, NA-1
NoNO Inc., University of Calgary
Stroke, Acute
08/23
08/23
NoNO-42 / NoNO
ACT-GLOBAL, NCT06352632: Adaptive Platform Trial for Stroke

Recruiting
3
20000
Canada, RoW
Standard-dose intravenous tenecteplase, Low-dose intravenous tenecteplase, No intravenous tenecteplase, Conservative Blood Pressure Control, Moderate Blood Pressure Control, Intensive Blood Pressure Control, Placebo, NoNO-42, No deferoxamine mesylate and no colchicine, Deferoxamine mesylate only, Colchicine only, Both deferoxamine mesylate and colchicine
The George Institute, University of Calgary, Berry Consultants
Stroke
09/34
09/34
NCT06403267: NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis with or Without Endovascular Thrombectomy

Recruiting
2
600
Canada
NoNO-42, Placebo, Control
NoNO Inc.
Acute Ischemic Stroke
05/26
05/26
NCT05636306: A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy Adults

Completed
1
83
Canada
NoNO-42, Placebo
NoNO Inc.
First-In-Human Study to Evaluate Safety of a New Drug Intended for Treatment of Acute Ischemic Stroke
10/23
10/23
NoNO-SC / NoNO
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
nerinetide (NA 1) / NoNO
FRONTIER, NCT02315443: Field Randomization of Nerinetide (NA-1) Therapy in Early Responders

Completed
3
532
Canada
Nerinetide (NA-1), Placebo
NoNO Inc., Brain Canada, Djavad Mowafaghian Centre for Brain Health, Canadian Stroke Network, University of Calgary, University of Toronto, University of British Columbia, Genome British Columbia
Acute Cerebral Ischemia
03/23
03/23
ESCAPE-NEXT, NCT04462536 / 2020-002360-30: Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis

Completed
3
850
Europe, Canada, US, RoW
Placebo, Nerinetide, NA-1
NoNO Inc., University of Calgary
Stroke, Acute
08/23
08/23
NoNO-42 / NoNO
ACT-GLOBAL, NCT06352632: Adaptive Platform Trial for Stroke

Recruiting
3
20000
Canada, RoW
Standard-dose intravenous tenecteplase, Low-dose intravenous tenecteplase, No intravenous tenecteplase, Conservative Blood Pressure Control, Moderate Blood Pressure Control, Intensive Blood Pressure Control, Placebo, NoNO-42, No deferoxamine mesylate and no colchicine, Deferoxamine mesylate only, Colchicine only, Both deferoxamine mesylate and colchicine
The George Institute, University of Calgary, Berry Consultants
Stroke
09/34
09/34
NCT06403267: NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis with or Without Endovascular Thrombectomy

Recruiting
2
600
Canada
NoNO-42, Placebo, Control
NoNO Inc.
Acute Ischemic Stroke
05/26
05/26
NCT05636306: A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy Adults

Completed
1
83
Canada
NoNO-42, Placebo
NoNO Inc.
First-In-Human Study to Evaluate Safety of a New Drug Intended for Treatment of Acute Ischemic Stroke
10/23
10/23
NoNO-SC / NoNO
No trials found

Download Options